Nippon Kayaku Co., Ltd. company is divided into three primary business lines: functional chemicals, pharmaceuticals, and automotive safety parts (airbags, ignition parts). It also manufactures pesticides and herbicides. Its pharmaceuticals segment is focused on producing anti-cancer drugs and immunosuppressants as well as cardiovascular and neurological drugs (brand name and generics). Other products in its divisions include dyes, inflators for automobile airbags, industrial explosives, epoxy resins, and agricultural chemicals. Nippon Kayaku has offices, manufacturing plants, and laboratories in Japan, as well as operations in China, Germany, Taiwan, and the US.

Ironwood Pharmaceuticals (formerly Microbia) is a drug developer that is busy testing the gastrointestinal drug candidates in its pipeline. The company is developing lead drug candidate linaclotide, which is undergoing trials in partnership with Forest Laboratories and other co-developers for the treatment of irritable bowel syndrome, abdominal pain, and chronic constipation. The company's Microbia biotechnology subsidiary harnesses microbes to produce specialty chemicals from renewable resources with applications the agriculture, chemical, and pharmaceutical industries. Ironwood Pharmaceuticals made a move to go public when it filed for an IPO in 2009.

United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland. United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of therapeutic products for patients with chronic and life-threatening cardiovascular and infectious diseases, and cancer in the United States and Internationally. United's products include Remodulin (treprostinil sodium) for the treatment of pulmonary arterial hypertension; and CardioPAL SAVI and Decipher Cardiac Monitors for the treatment of cardiac arrhythmias and ischemic heart disease. Its NDA filed products include Inhaled Treprostinil for pulmonary arterial hypertension and Oral Tadalafil for pulmonary hypertension. United's Phase III products comprise of Oral Treprostinil for pulmonary arterial hypertension; and Phase II products include Beraprost-MR for pulmonary arterial hypertension, 3F8 MAb for neuroblastoma, Oral Treprostinil for Peripheral vascular disease, and CardioPAL SAVI Wireless Cardiac Event Monitors for Cardiac arrhythmias and ischemic heart disease. Its Phase I products include Inhaled Treprostinil for pulmonary arterial hypertension associated with Idiopathic pulmonary fibrosis, Inhaled Treprostinil with AERx Essence for Pulmonary hypertension, 8H9 MAb for Metastatic brain cancer, and Celgosivir for Hepatitis C. United's pre-clinical products comprise Miglustat for Hepatitis C and Glycobiology Antiviral Agents for Hepatitis C and other infectious diseases.

Allergy Research Group Inc. offers nutritional supplement products. It offers amino acids, antioxidant formulas, bioenergetics, bioflavonoids, blood sugar, books, brain, cardiovascular, comprehensive formulas, fatty acids, eye, gastric support, glandulars, and hormone products. Allergy Research Group also provides immune support, liver support, martin pall products, metabolic support, microbial balancers, minerals, multiples, musculoskeletal, probiotics, specialty products, vitamin B products, vitamin C products, and vitamin D, E, K products. The company was founded in 1979 and is headquartered in Alameda, California. As of September 9, 2008, Allergy Research Group Inc. operates as a subsidiary of KI NutriCare, Inc.

Vanda Pharmaceuticals was founded in 2002 and is headquartered in Rockville, Maryland. Vanda Pharmaceuticals Inc., a biopharmaceutical company, engages in the development and commercialization of clinical-stage drug candidates for central nervous system disorders. Its product portfolio includes Iloperidone (oral), a compound for the treatment of schizophrenia completed Phase III clinical trial; and Tasimelteon, which completed Phase III clinical trials for transient insomnia and chronic primary insomnia. The company's products also comprise Iloperidone (Injectible) for the treatment of schizophrenia and Tasimelteon for the treatment of depression, which are in the Phase II initiation status.

Anacor Pharmaceuticals is a biopharmaceutical company developing novel small-molecule therapeutics derived from its boron chemistry platform to treat infectious and inflammatory diseases. Anacor's most advanced product candidate is AN2690, a novel topical antifungal for the treatment of toenail onychomycosis, a fungal infection of the nail and nail bed. Anacor also has a portfolio of other topical product candidates in development for the treatment of psoriasis, atopic dermatitis and skin and nail fungal infections. The company has entered into a worldwide license, development and commercialization agreement with Merck for the development and commercialization of AN2690 for all indications including the treatment of onychomycosis. In addition, Anacor has a research and development agreement with GSK for novel antiviral and antibacterial systemic therapeutics.

Dako makes disease diagnosis a little more clear-cut. A leader in the area of pathology testing, Dako makes instrumentation systems, reagents, and software used by pathology laboratories to analyze human tissues for the presence of cancer. Its Automated Link line of pathology instruments include staining and visualization systems, chemical and antibody reagents, and Dako Link workflow management software. The company also makes reagents used in flow cytometry testing (which analyzes the cells in blood) and in clinical immunochemistry (which measures proteins in body fluids). The company was acquired by private equity fund EQT in 2007 and subsequently divested its flow cytometry instrumentation business.

The Boehringer Ingelheim group of companies is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, the privately–owned company currently has nearly 41,300 employees and 138 affiliated companies spread around the globe. Boehringer Ingelheim is research-driven and dedicated to the discovery, development, manufacture and marketing of innovative human and animal health care products.

FibroGen, Inc. company is focused on developing and commercializing treatments for fibrosis, anemia, diabetes, and cancer, as well as producing recombinant human collagens and synthetic gelatins. FibroGen has several products in clinical development, including: FG-3019, a monoclonal antibody that may treat a variety of conditions including diabetic nephropathy; FG-2216, an orally administered small molecule drug in development for the treatment of anemia; FG-5017, a recombinant version of human collagen; and FG-5009, a synthetic gelatin molecule designed to stabilize vaccines and biologics. The company commenced lab operations in 1995.

Cellectis SA company develops technologies involving the research and development of rational genome engineering (making changes in the genetics of a cell or organism). The company's research is primarily based on the Meganucleasus, a natural classification of DNA that isolates unique breaks at key locations within living cells. Its patented Meganuclease Recombination Systems technology helps to initiate the rational genome engineering process, which in turn can help treat diseases and augment genetic codes.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.